Groups Target EU-Mercosur FTA To Advance Access To Health In Trade Deals16/05/2018 by Monika Ermert for Intellectual Property Watch 12 CommentsAIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of the planned free trade agreement between the Mercosur countries and the European Union. The EU-Mercosur negotiations might be the best chance as of now to advance an intellectual property agenda that is more favourable to access to health, says Pedro Villardi, coordinator on IP policy issues at the Associação Brasiliera Interdisciplinar de Aids Observatorio National de Politicas de Aids (ABIA).
WHO Issues First-Ever List Of Essential Diagnostic Tests15/05/2018 by Intellectual Property Watch 2 CommentsThe World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases.
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System11/05/2018 by William New, Intellectual Property Watch 2 CommentsUS President Trump today declared in a White House speech his intent to “take steps” to lower drug prices by stopping “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies,” as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as “freeloading” on US innovation by foreign governments, and addressing “unfair” intellectual property and market access policies in trade agreements.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents10/05/2018 by Catherine Saez, Intellectual Property Watch 10 CommentsMany hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition08/05/2018 by Catherine Saez, Intellectual Property Watch 10 CommentsThe example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim07/05/2018 by Sinfah Tunsarawuth for Intellectual Property Watch 7 CommentsBANGKOK – Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.
Unitaid Calls For Proposals On TB, Hails New Insecticide07/05/2018 by Intellectual Property Watch Leave a CommentUnitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes.
Civil Society Key In TRIPS Flexibility Implementation04/05/2018 by Catherine Saez, Intellectual Property Watch 18 CommentsWhen the agreement on intellectual property was adopted by the World Trade Organization, a number of flexibilities were included in the text, mainly to give developing countries policy space to implement the agreement with development considerations. However, some countries through lack of awareness or economic pressure have not used those flexibilities fully, and found themselves facing difficulties addressing their public health needs, which some associate with this failure to use the flexibilities. Civil society has engaged in notable efforts to counter pressure and raise policymakers’ awareness for a wider access to medicines.
Brazil’s Federal Court Reviews Medicines Mailbox Patents04/05/2018 by Intellectual Property Watch 1 CommentThis week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is.
World Health Assembly 2018 Preview: Guide To Key Issues03/05/2018 by Catherine Saez, Intellectual Property Watch 3 CommentsThe World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage.
